Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer

Authors

Jeffrey I. Zwicker, Division of Hemostasis and Thrombosis and
Benjamin L. Schlechter, Harvard Medical School
Jack D. Stopa, Division of Hemostasis and Thrombosis and
Howard A. Liebman, University of Southern California
Anita Aggarwal, VA Medical Center
Maneka Puligandla, Dana-Farber Cancer Institute
Thomas Caughey, Mount Auburn Hospital
Kenneth A. Bauer, Division of Hemostasis and Thrombosis and
Nancy Kuemmerle, White River Junction VA Medical Center
Ellice Wong, VA Connecticut Healthcare System
Ted Wun, UC Davis School of Medicine
Marilyn McLaughlin, York Hospital
Manuel Hidalgo, Harvard Medical School
Donna Neuberg, Dana-Farber Cancer Institute
Bruce Furie, Division of Hemostasis and Thrombosis and
Robert Flaumenhaft, Division of Hemostasis and Thrombosis and

Document Type

Journal Article

Publication Date

2-21-2019

Journal

JCI insight

Volume

4

Issue

4

DOI

10.1172/jci.insight.125851

Keywords

Clinical Trials; Coagulation; Hematology; Thrombosis

APA Citation

Zwicker, J., Schlechter, B., Stopa, J., Liebman, H., Aggarwal, A., Puligandla, M., Caughey, T., Bauer, K., Kuemmerle, N., Wong, E., Wun, T., McLaughlin, M., Hidalgo, M., Neuberg, D., Furie, B., & Flaumenhaft, R. (2019). Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI insight, 4 (4). http://dx.doi.org/10.1172/jci.insight.125851